Final data from the phase 2a single-arm trial of SurVaxM for newly diagnosed glioblastoma

被引：0
|
作者：
Ciesielski, Michael J.
Ahluwalia, Manmeet Singh
Reardon, David A.
Abad, Ajay P.
Curry, William T.
Wong, Eric T.
Peereboom, David M.
Figel, Sheila A.
Hutson, Alan
Groman, Adrienne
Withers, Henry G.
Liu, Song
Belal, Ahmed
Qiu, Jing-Xin
Mogensen, Kathleen
Schilero, Cathy
Casucci, Danielle M.
Mechtler, Laszlo
Fenstermaker, Robert Alan
机构：
[1] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
[2] Taussig Canc Inst, Neurol Inst, Rose Ella Burkhardt Brain Tumor & Neuro Oncol Ctr, Cleveland, OH USA
[3] Cleveland Clin, Cleveland, OH USA
[4] Dana Farber Canc Inst, Boston, MA USA
[5] Harvard Med Sch, Boston, MA USA
[6] Massachusetts Gen Hosp, Boston, MA USA
[7] Beth Israel Deaconess Med Ctr, Boston, MA USA
[8] MimiVax, Buffalo, NY USA
[9] Dent Neurol Inst, Buffalo, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2037
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PHASE II TRIAL OF A SURVIVIN VACCINE (SurVaxM) FOR NEWLY DIAGNOSED GLIOBLASTOMA
    Ahluwalia, Manmeet
    Reardon, David
    Abad, Ajay
    Curry, William
    Wong, Eric
    Peereboom, David
    Belal, Ahmed
    Qiu, Jingxin
    Mogensen, Kathleen
    Schilero, Cathy
    Casucci, Danielle
    Mechtler, Laszlo
    Uhlmann, Erik
    Ciesielski, Michael
    Fenstermaker, Robert
    NEURO-ONCOLOGY, 2018, 20 : 10 - 11
  • [2] PHASE II TRIAL OF SURVAXM PLUS TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA
    Ahluwalia, Manmeet
    Ciesielski, Michael J.
    Reardon, David A.
    Abad, Ajay
    Curry, William
    Wong, Eric
    Peereboom, David
    Figel, Sheila
    Hutson, Alan
    Groman, Adrienne
    Withers, Henry
    Liu, Song
    Belal, Ahmed
    Qiu, Jingxin
    Mogensen, Kathleen
    Schilero, Cathy
    Khosla, Atulya
    Casucci, Danielle
    Mechtler, Laszlo
    Fenstermaker, Robert
    NEURO-ONCOLOGY, 2022, 24 : 66 - 66
  • [3] SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update.
    Ahluwalia, Manmeet Singh
    Reardon, David A.
    Abad, Ajay P.
    Curry, William T.
    Wong, Eric T.
    Belal, Ahmed
    Qiu, Jingxin
    Mogensen, Kathleen
    Schilero, Cathy
    Hutson, Alan
    Casucci, Danielle
    Mechtler, Laszlo
    Uhlmann, Erik J.
    Ciesielski, Michael J.
    Fenstermaker, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase Ⅱ trial
    Shuzhen Lai
    Peijing Li
    Xiaohui Liu
    Guihong Liu
    Tieming Xie
    Xing Zhang
    Xiaoxuan Wang
    Jing Huang
    Yiqiang Tang
    Zhigang Liu
    Guoping Shen
    Chaoming Li
    Fangxiao Lu
    Lei Wang
    Fagui Jiang
    Caixing Sun
    Yuanyuan Chen
    Ming Chen
    Cancer Biology & Medicine, 2024, 21 (05) : 433 - 444
  • [5] Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma.
    Ahluwalia, Manmeet Singh
    Reardon, David A.
    Abad, Ajay P.
    Curry, William T.
    Wong, Eric T.
    Belal, Ahmed
    Qiu, Jingxin
    Mogensen, Kathleen
    Schilero, Cathy
    Casucci, Danielle
    Mechtler, Laszlo
    Uhlmann, Erik J.
    Ciesielski, Michael J.
    Fenstermaker, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial
    Lai, Shuzhen
    Li, Peijing
    Liu, Xiaohui
    Liu, Guihong
    Xie, Tieming
    Zhang, Xing
    Wang, Xiaoxuan
    Huang, Jing
    Tang, Yiqiang
    Liu, Zhigang
    Shen, Guoping
    Li, Chaoming
    Lu, Fangxiao
    Wang, Lei
    Jiang, Fagui
    Sun, Caixing
    Chen, Yuanyuan
    Chen, Ming
    CANCER BIOLOGY & MEDICINE, 2024, 21 (05)
  • [7] Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial
    Ji, Nan
    Zhang, Yang
    Liu, Yunpeng
    Xie, Jian
    Wang, Yi
    Hao, Shuyu
    Gao, Zhixian
    JCI INSIGHT, 2018, 3 (10):
  • [8] PriCoTTF: A phase I/II single-arm trial of tumor treating fields prior and concomitant with radiotherapy and temozolomide in newly diagnosed glioblastoma
    Glas, M.
    Scheffler, B.
    Lazaridis, L.
    Herrlinger, U.
    Pierscianek, D.
    El Hindy, N.
    Sure, U.
    Proescholdt, M.
    Hau, P.
    Hense, J.
    Kleinschnitz, C.
    Combs, S. E.
    Grosu, A. -L.
    Stuschke, M.
    Kebir, S.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 : S73 - S73
  • [9] Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma
    Ahluwalia, Manmeet S.
    Reardon, David A.
    Abad, Ajay P.
    Curry, William T.
    Wong, Eric T.
    Figel, Sheila A.
    Mechtler, Laszlo L.
    Peereboom, David M.
    Hutson, Alan D.
    Withers, Henry G.
    Liu, Song
    Belal, Ahmed N.
    Qiu, Jingxin
    Mogensen, Kathleen M.
    Dharma, Sanam S.
    Dhawan, Andrew
    Birkemeier, Meaghan T.
    Casucci, Danielle M.
    Ciesielski, Michael J.
    Fenstermaker, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (07) : 1453 - +
  • [10] Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma
    Grossman, Stuart A.
    Schreck, Karisa C.
    Ballman, Karla
    Alexander, Brian
    NEURO-ONCOLOGY, 2017, 19 (04) : 469 - 474
12345